Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Institutional pharmacies | | | | | | | | 1.8 |
| Hospital pharmacy management | | | | | | | | 0.1 |
| (As Adjusted) | | | | | | | | 1.8 |
| Medicare | | | | | | | 7.4 | |
| Other | | | | | | | 1,839.9 | 1,837.5 |
| Total revenues | 2,091.1 | 2,028.5 | 1,894.5 | 1,757.9 | 1,832.6 | 2,081.1 | 1,847.3 | 1,841.2 |
| Revenue growth [+] | 3.1% | 7.1% | 7.8% | -4.1% | -11.9% | 12.7% | 0.3% | -5.4% |
| Institutional pharmacies | | | | | | | | -99.9% |
| Hospital pharmacy management | | | | | | | | -99.9% |
| Cost of goods sold | 1,765.1 | 1,693.4 | 1,555.2 | 1,430.7 | 1,532.4 | 1,786.2 | 1,604.8 | 1,565.7 |
| Gross profit | 326.0 | 335.1 | 339.3 | 327.2 | 300.2 | 294.9 | 242.5 | 275.5 |
| Gross margin | 15.6% | 16.5% | 17.9% | 18.6% | 16.4% | 14.2% | 13.1% | 15.0% |
| Selling, general and administrative | 220.6 | 222.5 | 236.3 | 225.3 | 214.7 | 216.5 | 182.8 | 190.8 |
| Other operating expenses | 9.6 | 3.4 | 35.6 | 32.1 | 19.9 | 15.3 | 14.6 | 5.2 |
| EBITDA [+] | 119.6 | 132.3 | 87.7 | 89.1 | 84.2 | | 63.9 | 97.5 |
| EBITDA growth | -9.6% | 50.9% | -1.6% | 5.8% | 33.4% | -1.3% | -34.5% | 48.2% |
| EBITDA margin | 5.7% | 6.5% | 4.6% | 5.1% | 4.6% | 3.0% | 3.5% | 5.3% |
| Depreciation | 23.8 | 23.1 | 20.3 | 19.3 | 18.6 | | 18.8 | 18.0 |
| EBITA | 95.8 | 109.2 | 67.4 | 69.8 | 65.6 | 63.1 | 45.1 | 79.5 |
| EBITA margin | 4.6% | 5.4% | 3.6% | 4.0% | 3.6% | 3.0% | 2.4% | 4.3% |
| Amortization of intangibles | 33.7 | 28.6 | 20.1 | 15.4 | 12.3 | 11.0 | 9.3 | 9.0 |
| EBIT [+] | 62.1 | 80.6 | 47.3 | 54.4 | 53.3 | 52.1 | 35.8 | 70.5 |
| EBIT growth | -23.0% | 70.4% | -13.1% | 2.1% | 2.3% | 45.5% | -49.2% | 89.0% |
| EBIT margin | 3.0% | 4.0% | 2.5% | 3.1% | 2.9% | 2.5% | 1.9% | 3.8% |
| Non-recurring items [+] | 23.7 | 26.8 | 16.9 | -1.4 | 4.5 | 5.1 | | |
| Asset impairment | | | | | | 5.1 | | |
| Unusual expense | | 5.0 | | -1.4 | 4.5 | | | |
| Interest expense | 9.5 | 6.6 | 9.9 | 10.6 | 10.0 | 8.8 | 3.6 | 9.4 |
| Interest expense | 9.5 | 6.6 | 9.9 | 10.6 | 10.0 | 8.8 | 3.6 | 9.4 |
| Other income (expense), net [+] | | | -4.3 | | | | | |
| Gain (loss) on debt retirement | | | 4.3 | | | | | |
| Pre-tax income | 28.9 | 47.2 | 16.2 | 45.2 | 38.8 | 38.2 | 32.2 | 61.1 |
| Income taxes | 7.3 | 12.1 | 9.4 | 26.3 | 15.9 | 14.8 | 13.0 | 18.9 |
| Tax rate | 25.3% | 25.6% | 58.0% | 58.2% | 41.0% | 38.7% | 40.4% | 30.9% |
| Net income | 21.6 | 35.1 | 6.8 | 18.9 | 22.9 | 23.4 | 19.2 | 42.2 |
| Net margin | 1.0% | 1.7% | 0.4% | 1.1% | 1.2% | 1.1% | 1.0% | 2.3% |
| |
| Basic EPS [+] | $0.70 | $1.16 | $0.23 | $0.64 | $0.78 | $0.80 | $0.64 | $1.39 |
| Growth | -39.1% | 409.7% | -64.5% | -17.8% | -2.6% | 24.6% | -54.1% | 739.2% |
| Diluted EPS [+] | $0.69 | $1.14 | $0.22 | $0.63 | $0.77 | $0.79 | $0.64 | $1.39 |
| Growth | -39.2% | 414.2% | -64.7% | -17.9% | -3.6% | 24.6% | -54.1% | 738.1% |
| |
| Shares outstanding (basic) [+] | 30.7 | 30.4 | 30.0 | 29.6 | 29.5 | 29.3 | 30.0 | 30.3 |
| Growth | 1.1% | 1.3% | 1.3% | 0.4% | 0.4% | -2.2% | -0.9% | 0.6% |
| Shares outstanding (diluted) [+] | 31.2 | 30.8 | 30.6 | 30.1 | 29.9 | 29.5 | 30.1 | 30.4 |
| Growth | 1.3% | 0.4% | 1.9% | 0.6% | 1.5% | -2.2% | -0.9% | 0.7% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|